Cystic Diseases of the Kidney Medication
- Author: Thomas Patrick Frye, DO; Chief Editor: Bradley Fields Schwartz, DO, FACS more...
Medication Summary
No specific medical therapies are available for the renal cysts themselves. Complications of cystic renal diseases, such as hypertension, infection, and pain, are treated with standard medical therapy. Some examples are listed below.
Angiotensin-converting enzyme inhibitors
Class Summary
These agents reduce aldosterone secretion.
Lisinopril (Zestril, Prinivil)
Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in lower aldosterone secretion.
Angiotensin II receptor antagonists
Class Summary
These agents antagonize the effects of angiotensin II.
Losartan (Cozaar)
Nonpeptide angiotensin II receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. May induce a more complete inhibition of the renin-angiotensin system than ACE inhibitors, does not affect the response to bradykinin, and is less likely to be associated with cough and angioedema. For patients unable to tolerate ACE inhibitors.
Calcium channel blockers
Class Summary
In specialized conducting and automatic cells in the heart, calcium is involved in the generation of the action potential. The calcium channel blockers inhibit movement of calcium ions across the cell membrane, depressing both impulse formation (automaticity) and conduction velocity.
Diltiazem (Cardizem, Dilacor, Tiazac)
During depolarization, inhibits calcium ions from entering the slow channels and voltage-sensitive areas of vascular smooth muscle and myocardium.
Antimicrobials
Class Summary
These agents are used to treat renal parenchymal infection (to be used in combination with gentamicin) and infected renal cysts.
Ampicillin (Principen, Omnipen, Marcillin)
Bactericidal activity against susceptible organisms. Alternative to amoxicillin when patients are unable to take medication orally. Used to treat parenchymal infection.
Gentamicin (Garamycin, Gentacidin)
Aminoglycoside antibiotic for gram-negative coverage. Used in combination with both an agent against gram-positive organisms and one that covers anaerobes. Not the DOC, but consider if penicillins or other less toxic drugs are contraindicated, when clinically indicated, and in mixed infections caused by susceptible staphylococci and gram-negative organisms. Dosing regimens are numerous; adjust dose based on CrCl and changes in volume of distribution. May be administered IV/IM.
Sulfamethoxazole and trimethoprim (Bactrim, Bactrim DS, Septra, Septra DS)
Inhibits bacterial growth by inhibiting synthesis of dihydrofolic acid. Antibacterial activity of TMP-SMZ includes common urinary tract pathogens, except Pseudomonas aeruginosa. Used to treat infected renal cyst.
Ciprofloxacin (Cipro)
Fluoroquinolone with activity against pseudomonads, streptococci, MRSA, S epidermidis, and most gram-negative organisms, but no activity against anaerobes. Inhibits bacterial DNA synthesis and, consequently, growth. Trovafloxacin (Trovan) overcomes many of these limitations. Continue treatment for at least 2 d (7-14 d typical) after signs and symptoms have disappeared.
Used to treat infected renal cyst either in patients intolerant to or not adequately covered by trimethoprim-sulfasalazine.
Thiazide diuretics
Class Summary
These agents are beneficial in the treatment of fluid retention.
Hydrochlorothiazide (Microzide, Esidrix, HydroDIURIL)
Inhibits reabsorption of sodium in distal tubules, increasing excretion of sodium and water, as well as potassium and hydrogen ions.
Analgesics
Class Summary
Pain control is essential to quality patient care. Analgesics ensure patient comfort and have sedating properties, which are beneficial for patients who experience pain.
Oxycodone and acetaminophen (Percocet, Roxicet, Roxilox, Tylox)
Drug combination indicated for the relief of moderate-to-severe pain.
Bisceglia M, Galliani CA, Senger C, Stallone C, Sessa A. Renal cystic diseases: a review. Adv Anat Pathol. Jan 2006;13(1):26-56. [Medline].
Kalyoussef E, Hwang J, Prasad V, Barone J. Segmental multicystic dysplastic kidney in children. Urology. Nov 2006;68(5):1121.e9-11. [Medline].
Guay-Woodford LM. Renal cystic diseases: diverse phenotypes converge on the cilium/centrosome complex. Pediatr Nephrol. Oct 2006;21(10):1369-76. [Medline].
Thomsen HS, Levine E, Meilstrup JW, Van Slyke MA, Edgar KA, Barth JC, et al. Renal cystic diseases. Eur Radiol. 1997;7(8):1267-75. [Medline].
Choyke PL. Acquired cystic kidney disease. Eur Radiol. 2000;10(11):1716-21. [Medline].
Avner ED, Sweeney WE. Renal cystic disease: new insights for the clinician. Pediatr Clin North Am. Oct 2006;53(5):889-909, ix. [Medline].
Gunay-Aygun M, Avner ED, Bacallao RL, Choyke PL, Flynn JT, Germino GG, et al. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference. J Pediatr. Aug 2006;149(2):159-64. [Medline].
Saunier S, Salomon R, Antignac C. Nephronophthisis. Curr Opin Genet Dev. Jun 2005;15(3):324-31. [Medline].
Siqueira Rabelo EA, Oliveira EA, Silva JM, Oliveira DS, Colosimo EA. Ultrasound progression of prenatally detected multicystic dysplastic kidney. Urology. Nov 2006;68(5):1098-102. [Medline].
Welch TR, Wacksman J. The changing approach to multicystic dysplastic kidney in children. J Pediatr. Jun 2005;146(6):723-5. [Medline].
Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF, et al. Volume progression in polycystic kidney disease. N Engl J Med. May 18 2006;354(20):2122-30. [Medline].
Wilson PD. Polycystic kidney disease. N Engl J Med. Jan 8 2004;350(2):151-64. [Medline].
Gusmano R, Caridi G, Marini M, Perfumo F, Ghiggeri GM, Piaggio G, et al. Glomerulocystic kidney disease in a family. Nephrol Dial Transplant. May 2002;17(5):813-8. [Medline].
Onal B, Kogan BA. Natural history of patients with multicystic dysplastic kidney-what followup is needed?. J Urol. Oct 2006;176(4 Pt 1):1607-11. [Medline].
Mostov KE. mTOR is out of control in polycystic kidney disease. Proc Natl Acad Sci U S A. Apr 4 2006;103(14):5247-8. [Medline].
Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. PNAS. Apr 4 2006;103:5466-5471. [Medline].
Torres, Vicente, Harris, Peter, Yves, Pirson. Autosomal dominant polycystic kidney disease. The Lancet. April 14, 2007;369:1287-1301.
Mercado-Deane MG, Beeson JE, John SD. US of renal insufficiency in neonates. Radiographics. Nov-Dec 2002;22(6):1429-38. [Medline].
Borges Oliva MR, Hsing J, Rybicki FJ, Fennessy F, Mortele KJ, Ros PR. Glomerulocystic kidney disease: MRI findings. Abdominal Imaging. Nov 2003;28:889-892. [Medline].
Bosniak MA. The use of the Bosniak classification system for renal cysts and cystic tumors. J Urol. May 1997;157(5):1852-3. [Medline].
Song C., et al. Differential Diagnosis of Complex Cystic Renal Mass Using Multiphase Computerized Tomography. Journal of Urology. 2009/06;181:2446-2450.
Garcia-Rojo, D. Comparison of Contrast-Enhanced Ultrasound (CE-US) and Computed Tomography (CT) in the Evaluation of Complex Cystic Renal Masses. Journal of Urology. May 31, 2010;183:e243.
Li, G.,, et al. CA9 molecular marker for differential diagnosis of cystic renal tumors. Urologic Oncology. Sept. 3, 2010.
Torres VE, Harris PC. Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol. Jan 2006;2(1):40-55; quiz 55. [Medline].
Zerem, E. Simple renal cysts and arterial hypertension: does their evacuation decrease the blood pressure?. Journal of Hypertension. Oct. 27, 2009;10:2074-2078.
Sweeney WE, Chen Y, Nakanishi K, Frost P, Avner ED. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. Jan 2000;57(1):33-40. [Medline].
Aperis G. Tolvaptan: A new therapeutic agent. Review Recent Clinical Trials. Sept. 22, 2010.
Serra A., et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. New England Journal of Medicine. Aug. 26, 2010;9:820-829.
Rane, A. Laparoscopic management of symptomatic simple renal cysts. International Urology Nephrology. 2004;36:5-9.
Emre, H. "Stepped procedure" in laparoscopic cyst decortications during the learning period of laparoscopic surgery: Detailed evaluation of initial experiences. Journal of Minimal Access Surgery. Apr 6, 2010;2:37-41.
Kilciler, M. Finger assisted laparoscopic renal cyst excision: a simple technique. Urology Journal. Jun 10, 2010;7:90-94.
Busato, W. Percutaneous endocystolysis, a safe and minimally invasive treatment for renal cysts: a 13-year experience. Journal of Endourology. Sept. 2010;24:1405-1410.
Lucas, S. Staged Nephrectomy Versus Bilateral Laparoscopic Nephrectomy in Patients with Autosomal Dominant Polycycstic Kidney Disease. Journal of Urology. Nov. 2010;184:2054-2059.
Webster, W. Surgical Resection Provides Excellent Outcomes for Patients with Cystic Clear Cell Renal Cell Carcinoma. Urology. May 2007;900-904.
Bloom DA, Brosman S. The multicystic kidney. J Urol. Aug 1978;120(2):211-5. [Medline].
Bonsib SM. Non-neoplastic diseases of the kidney. In: Bostwick DG. Urologic Surgical Pathology. St Louis, Mo: Mosby-Year Book; 1997.
Bosniak MA. How does one deal with a renal cyst that appears to be Bosniak class II on a CT scan but that has sonographic features suggestive of malignancy (e.g., nodularity of wall or a nodular, irregular septum)?. AJR Am J Roentgenol. Jul 1994;163(1):216. [Medline].
Bosniak MA. The current radiological approach to renal cysts. Radiology. Jan 1986;158(1):1-10. [Medline].
Brook-Carter PT, Peral B, Ward CJ, Thompson P, Hughes J, Maheshwar MM, et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease--a contiguous gene syndrome. Nat Genet. Dec 1994;8(4):328-32. [Medline].
Chauveau D, Duvic C, Chretien Y, Paraf F, Droz D, Melki P, et al. Renal involvement in von Hippel-Lindau disease. Kidney Int. Sep 1996;50(3):944-51. [Medline].
Clarke A, Hancock E, Kingswood C, Osborne JP. End-stage renal failure in adults with the tuberous sclerosis complex. Nephrol Dial Transplant. Apr 1999;14(4):988-91. [Medline].
Davidson AJ, Hartman DS, Choyke PL, Wagner BJ. Radiologic assessment of renal masses: implications for patient care. Radiology. Feb 1997;202(2):297-305. [Medline].
Fick GM, Johnson AM, Hammond WS, Gabow PA. Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. Jun 1995;5(12):2048-56. [Medline].
Freire M, Remer EM. Clinical and radiologic features of cystic renal masses. AJR Am J Roentgenol. May 2009;192(5):1367-72. [Medline].
Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. Oct 2 2008;359(14):1477-85. [Medline].
Grantham JJ, Nair V, Winklhofer F. Cystic disease of the kidney. In: Brenner BM, ed. Brenner and Rector's the Kidney. 6th ed. Philadelphia, Pa: WB Saunders Co; 2000:1171-1200.
Israel GM, Bosniak MA. Follow-up CT of moderately complex cystic lesions of the kidney (Bosniak category IIF). AJR Am J Roentgenol. Sep 2003;181(3):627-33. [Medline].
Israel GM, Hindman N, Bosniak MA. Evaluation of cystic renal masses: comparison of CT and MR imaging by using the Bosniak classification system. Radiology. May 2004;231(2):365-71. [Medline].
Lang EK, Macchia RJ, Gayle B, Richter F, Watson RA, Thomas R. CT-guided biopsy of indeterminate renal cystic masses (Bosniak 3 and 2F): accuracy and impact on clinical management. Eur Radiol. Oct 2002;12(10):2518-24. [Medline].
Laube M, Hess B, Terrier F, Vock P, Jaeger P. [Prevalence of medullary sponge kidney in patients with and without nephrolithiasis]. Schweiz Rundsch Med Prax. Oct 24 1995;84(43):1224-30. [Medline].
Levine E, Slusher SL, Grantham JJ, Wetzel LH. Natural history of acquired renal cystic disease in dialysis patients: a prospective longitudinal CT study. AJR Am J Roentgenol. Mar 1991;156(3):501-6. [Medline].
Lonergan GJ, Rice RR, Suarez ES. Autosomal recessive polycystic kidney disease: radiologic-pathologic correlation. Radiographics. May-Jun 2000;20(3):837-55. [Medline].
Matson MA, Cohen EP. Acquired cystic kidney disease: occurrence, prevalence, and renal cancers. Medicine (Baltimore). Jul 1990;69(4):217-26. [Medline].
Miller MA, Brown JJ. Renal cysts and cystic neoplasms. Magn Reson Imaging Clin N Am. Feb 1997;5(1):49-66. [Medline].
Ohlson L. Normal collecting ducts: visualization at urography. Radiology. Jan 1989;170(1 Pt 1):33-7. [Medline].
Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet. Apr 2 1994;343(8901):824-7. [Medline].
Siegel CL, McFarland EG, Brink JA, Fisher AJ, Humphrey P, Heiken JP. CT of cystic renal masses: analysis of diagnostic performance and interobserver variation. AJR Am J Roentgenol. Sep 1997;169(3):813-8. [Medline].
Silverman SG, Israel GM, Herts BR, Richie JP. Management of the incidental renal mass. Radiology. Oct 2008;249(1):16-31. [Medline].
Wolf JS Jr. Evaluation and management of solid and cystic renal masses. J Urol. Apr 1998;159(4):1120-33. [Medline].
Yent ER. Medullary sponge kidney. In: Schrier RE, Gottschalk CW. Disease of the Kidney. 5th ed. Little Brown: Boston, Mass; 1993:525-32.

